|
Chimeric Antigen Receptor T (CAR-T) cell therapy is a genetic engineering technology that transforms a patient’s own T-cells to express receptors on their surface that can recognize specific antigens of tumor cells. The modified T-cells are thus able to accurately recognize and kill tumor cells, thus achieving the purpose of cancer treatment.
Currently, CAR-T therapy has demonstrated significant efficacy in the treatment of certain types of cancer, such as certain lymphomas and leukemias, and is gradually expanding to solid tumors and autoimmune diseases.
With years of expertise in protein, antibody, and ELISA kit development, CUSABIO possesses an extensive range of research reagents for viral studies and provides high-quality technical services. We are dedicated to supporting various stages of CAR-T cell therapy development, including CAR development, CAR-T preparation, CAR-T cell quality control and preclinical evaluation.
|
